694B3BE3-104F-4D90-8733-4E99230EFAC6
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 23.78449408672799
- age_years
- 19
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.459
- NOTCH_SIGNALING+0.456
- MYC_TARGETS_V2+0.428
- WNT_BETA_CATENIN_SIGNALING+0.414
- TGF_BETA_SIGNALING+0.369
- G2M_CHECKPOINT+0.329
- MITOTIC_SPINDLE+0.301
- DNA_REPAIR+0.291
- UNFOLDED_PROTEIN_RESPONSE+0.290
- E2F_TARGETS+0.233
Top 10 suppressed
- KRAS_SIGNALING_DN-0.436
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.354
- MYOGENESIS-0.298
- BILE_ACID_METABOLISM-0.281
- PANCREAS_BETA_CELLS-0.270
- ESTROGEN_RESPONSE_LATE-0.264
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.258
- COAGULATION-0.234
- TNFA_SIGNALING_VIA_NFKB-0.231
- UV_RESPONSE_UP-0.204
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934853 | — | — | 0.910 |
| 2 | 7FB45FBA-A0DE-4A56-8D24-C6ED09998EC3 | — | — | 0.889 |
| 3 | SRR934847 | — | — | 0.887 |
| 4 | F99D2B23-A7C3-4115-AA68-17AE6914AC2A | — | — | 0.887 |
| 5 | SRR934880 | — | — | 0.886 |
| 6 | 1AF24109-5FE4-4868-ADB9-5DFDB57BCA0F | — | — | 0.882 |
| 7 | 4FC69960-8EF2-49FE-A718-7004E99E00A8 | — | — | 0.878 |
| 8 | 0D1652B9-93F6-4D1A-BF06-B654663C92E3 | — | — | 0.872 |
| 9 | A1E55AC6-A41F-454A-A3B6-8F49D2AAFEF2 | — | — | 0.871 |
| 10 | DD028798-C4CB-43A8-81D7-711E015E23B5 | — | — | 0.870 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.459 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.456 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.428 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.414 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.369 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.329 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.301 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.291 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.290 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.233 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.231 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.069 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.063 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.047 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.046 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.034 | Remibrutinib | — uncovered |